Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types
- Age
- 21 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 20,000 (estimated)
- Sponsor
- ClearNote Health · Industry
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityClearNote Health is developing a test from whole blood for the early detection of multiple cancers. The goal of this study is to employ genomics, epigenomics and proteomics methodology for the detection of cancer signal in the blood of subjects with solid tumors.
Loading trial locations…